Drugs / CID-078
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06577987 | Aug 2024 → Jan 2027 expected | lung cancer, metastatic neoplasm, neuroendocrine carcinoma, refractory malignant neoplasm +1 | Circle Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-08-20 | Circle Pharma | Results Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition circlepharma.com ↗ |
| 2025-06-16 | Circle Pharma | Regulatory Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer circlepharma.com ↗
Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CID-078 for the treatment of small cell lung cancer (SCLC). |
| 2025-05-27 | Circle Pharma | Results Preclinical Data on Circle Pharma’s CID-078 Featured in Poster Presentation at Advances in Neuroblastoma Research Meeting circlepharma.com ↗
Potent Single agent CID-078 activity was observed across multiple neuroblastoma cell line models. |
| 2024-12-09 | Circle Pharma | Results Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024 circlepharma.com ↗
The pre-clinical data showed CID-078 demonstrated single agent antitumor activity with CID-078 in preclinical models of triple-negative breast cancer (TNBC) and estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer following CDK4/6 inhibitor (CDK4/6i) therapy. |
| 2024-10-23 | Circle Pharma | Results Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium circlepharma.com ↗
The pre-clinical data shows CID-078 demonstrated single-agent tumor activity across tumor cell line and in vivo models with dysregulated cell cycle (CDK-RB-E2F) function. |
| 2024-09-09 | Circle Pharma | Results Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer circlepharma.com ↗
CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, demonstrated single-agent tumor regressions in both small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) preclinical models. |
| 2024-07-01 | Circle Pharma | Regulatory Circle Pharma files first Investigational New Drug Application for First-in-Class Oral Cyclin A/B RxL Inhibitor for Treatment of Advanced Solid tumors circlepharma.com ↗
Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CID-078, a first-and-only-in-class cyclin A/B RxL inhibitor. |
| 2023-10-23 | Circle Pharma | Results Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor Presented at 2023 AACR-NCI-EORTC International Conference circlepharma.com ↗
The study in 40 breast cancer cell lines identified an association between hallmark pathway scores in E2F, G2/M, and mitotic spindle pathways and sensitivity to Cyclin A/B inhibition. |
All press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CID-078 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06577987 ↗ |
| Action | Inhibit | “CID-078, a Cyclin A/B-RxL inhibitor” NCT06577987 ↗ |
| Route | Oral | “CID-078 will be evaluated as an oral therapeutic.” NCT06577987 ↗ |